CHANNEL THERAPEUTICS CORP (CHRO) Fundamental Analysis & Valuation

NYSEARCA:CHRO • US1711261057

1.35 USD
+0.09 (+7.14%)
At close: Jul 1, 2025
1.3699 USD
+0.02 (+1.47%)
After Hours: 7/1/2025, 9:36:41 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CHRO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

0

Overall CHRO gets a fundamental rating of 0 out of 10. We evaluated CHRO against 519 industry peers in the Biotechnology industry. Both the profitability and financial health of CHRO have multiple concerns. CHRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. CHRO Profitability Analysis

1.1 Basic Checks

  • In the past year CHRO has reported negative net income.
  • CHRO had a negative operating cash flow in the past year.
  • CHRO had negative earnings in each of the past 5 years.
  • CHRO had a negative operating cash flow in each of the past 5 years.
CHRO Yearly Net Income VS EBIT VS OCF VS FCFCHRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

  • The Return On Assets of CHRO (-810.01%) is worse than 97.33% of its industry peers.
Industry RankSector Rank
ROA -810.01%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHRO Yearly ROA, ROE, ROICCHRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

  • CHRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CHRO Yearly Profit, Operating, Gross MarginsCHRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. CHRO Health Analysis

2.1 Basic Checks

  • CHRO has more shares outstanding than it did 1 year ago.
  • CHRO has a better debt/assets ratio than last year.
CHRO Yearly Shares OutstandingCHRO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M
CHRO Yearly Total Debt VS Total AssetsCHRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500K 1M 1.5M 2M

2.2 Solvency

  • CHRO has an Altman-Z score of -65.44. This is a bad value and indicates that CHRO is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of CHRO (-65.44) is worse than 94.48% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -65.44
ROIC/WACCN/A
WACCN/A
CHRO Yearly LT Debt VS Equity VS FCFCHRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

2.3 Liquidity

  • CHRO has a Current Ratio of 0.18. This is a bad value and indicates that CHRO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CHRO has a worse Current ratio (0.18) than 95.73% of its industry peers.
  • CHRO has a Quick Ratio of 0.18. This is a bad value and indicates that CHRO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.18, CHRO is doing worse than 95.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.18
Quick Ratio 0.18
CHRO Yearly Current Assets VS Current LiabilitesCHRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. CHRO Growth Analysis

3.1 Past

  • The earnings per share for CHRO have decreased strongly by -197.60% in the last year.
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 5.16% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.62%
EPS Next 2Y5.98%
EPS Next 3Y5.16%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CHRO Yearly Revenue VS EstimatesCHRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 50K 100K 150K
CHRO Yearly EPS VS EstimatesCHRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. CHRO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CHRO. In the last year negative earnings were reported.
  • Also next year CHRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHRO Price Earnings VS Forward Price EarningsCHRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CHRO Per share dataCHRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.98%
EPS Next 3Y5.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CHRO Dividend Analysis

5.1 Amount

  • CHRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CHRO Fundamentals: All Metrics, Ratios and Statistics

CHANNEL THERAPEUTICS CORP

NYSEARCA:CHRO (7/1/2025, 9:36:41 PM)

After market: 1.3699 +0.02 (+1.47%)

1.35

+0.09 (+7.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27
Earnings (Next)N/A
Inst Owners9.43%
Inst Owner ChangeN/A
Ins Owners14.91%
Ins Owner Change0%
Market Cap8.14M
Revenue(TTM)N/A
Net Income(TTM)-7.38M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0
BVpS-0.7
TBVpS-0.7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -810.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.18
Quick Ratio 0.18
Altman-Z -65.44
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.21%
EPS Next Y-3.62%
EPS Next 2Y5.98%
EPS Next 3Y5.16%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-196.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.4%
OCF growth 3YN/A
OCF growth 5YN/A

CHANNEL THERAPEUTICS CORP / CHRO FAQ

Can you provide the ChartMill fundamental rating for CHANNEL THERAPEUTICS CORP?

ChartMill assigns a fundamental rating of 0 / 10 to CHRO.


What is the valuation status of CHANNEL THERAPEUTICS CORP (CHRO) stock?

ChartMill assigns a valuation rating of 0 / 10 to CHANNEL THERAPEUTICS CORP (CHRO). This can be considered as Overvalued.


What is the profitability of CHRO stock?

CHANNEL THERAPEUTICS CORP (CHRO) has a profitability rating of 0 / 10.